Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C29H53INO4P |
| Molecular Weight | 641.6153 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CCOP([O-])(=O)OCCCCCCCCCCCCCCCCCCC1=CC=C([131I])C=C1
InChI
InChIKey=ZOAIEFWMQLYMTF-YRKXUXMHSA-N
InChI=1S/C29H53INO4P/c1-31(2,3)25-27-35-36(32,33)34-26-19-17-15-13-11-9-7-5-4-6-8-10-12-14-16-18-20-28-21-23-29(30)24-22-28/h21-24H,4-20,25-27H2,1-3H3/i30+4
| Molecular Formula | C29H53INO4P |
| Molecular Weight | 641.6153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
NM404 I-131 (also known as CLR 131) is a phospholipid ether analog labeled with iodine I-131, used as radiotherapeutic and positron emission tomography (PET) radioimaging agent. Upon infusion, the drug accumulates in tumor cells and is retained for a long time because of the decreased activity of a phospholipase D. The drug is being developed by Cellectar Biosciences and is investigated in clinical trials against multiple myeloma and hematologic malignancies. In 2014, the FDA granted orphan drug designation for CLR 131 for the treatment of multiple myeloma.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:32:44 GMT 2025
by
admin
on
Mon Mar 31 20:32:44 GMT 2025
|
| Record UNII |
R048696O9L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
455614
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
||
|
FDA ORPHAN DRUG |
651018
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
||
|
FDA ORPHAN DRUG |
638418
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
||
|
FDA ORPHAN DRUG |
646918
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
||
|
FDA ORPHAN DRUG |
629018
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
||
|
FDA ORPHAN DRUG |
716119
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
R048696O9L
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
PRIMARY | |||
|
100000178205
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
PRIMARY | |||
|
873438-88-1
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
PRIMARY | |||
|
DB15244
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
PRIMARY | |||
|
16045365
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
PRIMARY | |||
|
11916
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
PRIMARY | |||
|
C84879
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
PRIMARY | |||
|
SUB193827
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
PRIMARY | |||
|
C107500
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
SUPERSEDED | |||
|
HI-246
Created by
admin on Mon Mar 31 20:32:44 GMT 2025 , Edited by admin on Mon Mar 31 20:32:44 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
NON-LABELED -> LABELED |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|